Home › Companies › TTRX

Turn Therapeutics

Market cap $261M 30.6M shares (10-Q, Nov 6, 2026) × $8.55 close Nov 17, 2026

Most recent annual filing: 2026-03-31

Catalyst timeline

3 trackedQuarter catalyst calendar →
  1. GX-03 eczema Ph2 topline1Q 2027GX-03 eczema Ph2 topline, 1Q 2027, thesis-defining
  2. GX-03 onychomycosis Ph3 start1Q 2027GX-03 onychomycosis Ph3 start, 1Q 2027, routine
  3. PermaFusion onychomycosis Ph3 start1Q 2027PermaFusion onychomycosis Ph3 start, 1Q 2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (4 active programs)

intranasal influenza vaccine

Technology platforms

PermaFusion · Medline

PermaFusion is an oil-based suspension delivery platform enabling uniform delivery of water-soluble actives without emulsifiers; applications include thermostable intranasal live vaccine stabilization and dermatologic/antifungal product formulations. Focus areas include vaccines and dermatology.

PermaFusion

Multi-patented, API-agnostic topical drug delivery platform enabling stable, emulsifier-free dispersion of active ingredients in oil-based carriers; delivers APIs through skin, nails, and mucous membranes via suspended nanodroplets in petrolatum matrix; compatible with liquid or liquid-soluble APIs including live payloads; focus on dermatological and inflammatory diseases

Capital (as filed)

Cash
$9.4M cash and cash equivalents · Sep 30, 2026 (10-Q)
Operating cash flow
−$1.5M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$10.4M cash, runway Q3 2027 per the update of Nov 9, 2026 — the company's own words as read there, not the filed figure

Offering documents (2)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (12)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (12 calls)

Every verdict Biotech Distilled has published on Turn Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Watch Turn Therapeutics (TTRX) - Scientific Deep Dive for GX-03 and Pipeline Products Fascinating PermaFusion delivery platform but toxic GEM financing structure and binary Phase 2 readout make it too risky to buy now; wait for data.
  2. Watch UPDATE: Turn Therapeutics (TTRX) - TTRX Buys Time with a $25M Lifeline... Avenue Capital debt extends runway through Phase 2 readout but mortgages the PermaFusion IP and doesn't eliminate GEM dilution risk; stay on sidelines until data.
  3. Watch UPDATE: Turn Therapeutics (TTRX) - The Interim Clock Just Moved Up Interim readout now imminent in Q2 but Phase 3 budget tripled to $60-65M and buying into a binary interim is a speculative trade not an investment; wait for IAC decision.
  4. Watch UPDATE: Turn Therapeutics (TTRX) - A Former FDA Commissioner Walks Into a Pre-Readout Small-Cap Former FDA Commissioner Hahn joining as Executive Clinical and Regulatory Lead is meaningful self-selection and consistent with M&A setup, but stock is up 26% and asymmetric outcomes remain stark; still wait for IAC.
  5. Speculative buy speculative UPDATE: Turn Therapeutics (TTRX) - The Interim Drops, and the Vehicle Arm Did Not Get the Memo PermaFusion delivered measurable vehicle-controlled efficacy in human skin validating the platform, safety stayed clean, and M&A optionality sharpened, though vehicle response is high and Stage 2 enrollment refinement is a flag to monitor.
  6. Speculative buy speculative UPDATE: Turn Therapeutics (TTRX) - The Vehicle-Response Problem Just Got a Prospective Fix PP-NRS≥7 enrichment and Hochberg four-endpoint Stage 2 design address the vehicle-response problem with mechanism-consistent biology, runway extended to Q3 2027, and M&A choreography continues; hold existing positions but new entries at $9.71 are at a richer strike.
  7. Speculative buy speculative UPDATE: Turn Therapeutics (TTRX) - The GEM Facility Went Untouched Zero GEM draws in H1 2026 with only 1.2% share-count growth confirms management restraint; 99.8%-powered Stage 2 design and new HS indication add optionality, but going-concern language and $60-65M Phase 3 gap remain.
  8. Speculative buy speculative UPDATE: Turn Therapeutics (TTRX) - GEM Cashed In Its Chips GEM's cashless warrant exercise is 1.9% dilution with no cash to company, retiring one overhang but leaving $81M GEM capacity and Phase 3 funding gap intact; a technical supply event not a thesis break.
  9. Speculative buy speculative UPDATE: Turn Therapeutics (TTRX) - They Finally Sold Some Stock. Just Not to GEM. $1.65M 506(b) private placement to 8 accredited investors with no bank fees is non-punitive and banks 16.5% of the Avenue Tranche 2 equity gate; cumulative dilution ~3.7% over nine months confirms no death spiral.
  10. Speculative buy speculative UPDATE: Turn Therapeutics (TTRX) - First a Commissioner, Now a Director Former CDC Director Redfield as CSO fits the host-microbe immunology mechanism precisely and strengthens M&A legibility, but the +42.8% move is a credibility re-rating not a data re-rating and the Q4 binary is unchanged.
  11. Speculative buy speculative UPDATE: Turn Therapeutics (TTRX) - The Binary Slipped a Quarter Topline slipped one quarter to Q1 2027 with no explanation, Stage 1 p-values are thin (n=25 enriched subgroup), and Stage 2 is weighted toward low-EASI patients pointing to a narrower label, but trial design and Hochberg structure are unchanged.
  12. Hold UPDATE: Turn Therapeutics (TTRX) - The Lever Got Pulled First GEM draw in eleven months plus a $50M ATM program ends the financing discipline that underpinned the speculative buy; supply overhang into the Q1 2027 binary warrants downgrade to hold, though PJT M&A engagement is the clearest strategic signal yet.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (2 quotes from 2 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (44)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Mar 31, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

10 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)